Caspian Journal of Internal Medicine
Babol University of Medical Sciences
Thu, May 28, 2026
[Archive]
Volume 17, Issue 2 (Spring 2026)
Caspian J Intern Med 2026, 17(2): 22-0 |
Back to browse issues page
Ethics code: IR.GUMS.REC.1403.386
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Almasi M, Faraji N, Joukar F, Eslami N, Maroufizadeh S, Hojati A et al . Survival rate in patients with pancreatic cancer in Guilan province, Iran
Running title: Survival rate in patients with pancreatic cancer. Caspian J Intern Med 2026; 17 (2) :22-0
URL: http://caspjim.com/article-1-4887-en.html
URL: http://caspjim.com/article-1-4887-en.html
Mohammad Almasi * 
, Niloofar Faraji , Farahnaz Joukar , Narges Eslami , Saman Maroufizadeh , Amineh Hojati , Fariborz Mansour-Ghanaei
, Niloofar Faraji , Farahnaz Joukar , Narges Eslami , Saman Maroufizadeh , Amineh Hojati , Fariborz Mansour-Ghanaei
Gastrointestinal and Liver Diseases Research Center, Guilan University of Medical Sciences, Rasht, Iran , Dr_m.almasi@yahoo.com
Abstract: (101 Views)
Background: Pancreatic cancer is among the deadliest malignancies globally, marked by poor prognosis and limited survival. This research investigated the demographic and clinical determinants affecting overall survival in patients diagnosed with pancreatic cancer in Guilan Province, Iran.
Methods: A total of 50 pathologically and radiologically confirmed cases of pancreatic cancer were analyzed. Demographic, anthropometric, and clinical data were extracted from medical records. Survival probabilities were estimated using the Kaplan–Meier method, and intergroup differences were tested using the log-rank test. Cox proportional hazards modeling identified predictors of mortality, with significance defined at p < 0.05. Statistical analyses were conducted in SPSS (Version 16) and GraphPad Prism (v8).
Results: The majority of patients were males (60%) and over 60 years old (58%), while 46% had normal BMI and 40% had blood group O. Comorbidities were present in 42%, and 32% were diagnosed at stage IV. Mean and median survival were 39.6 and 9.0 months, respectively. One-, three-, and five-year survival rates were 45.2%, 31.3%, and 23.5%. Advanced tumor stage (III/IV) significantly predicted shorter survival (p < 0.001). Underweight individuals had higher mortality risk (HR = 2.79; 95% CI: 1.21–6.42; P = 0.016). In multivariate models, male gender, blood group O, and advanced disease remained independent negative prognostic indicators.
Conclusion: Male sex, advanced stage, low BMI, and blood group O were major determinants of poorer survival in pancreatic cancer. These results emphasize the need for individualized treatment and closer follow-up among high-risk groups.
Methods: A total of 50 pathologically and radiologically confirmed cases of pancreatic cancer were analyzed. Demographic, anthropometric, and clinical data were extracted from medical records. Survival probabilities were estimated using the Kaplan–Meier method, and intergroup differences were tested using the log-rank test. Cox proportional hazards modeling identified predictors of mortality, with significance defined at p < 0.05. Statistical analyses were conducted in SPSS (Version 16) and GraphPad Prism (v8).
Results: The majority of patients were males (60%) and over 60 years old (58%), while 46% had normal BMI and 40% had blood group O. Comorbidities were present in 42%, and 32% were diagnosed at stage IV. Mean and median survival were 39.6 and 9.0 months, respectively. One-, three-, and five-year survival rates were 45.2%, 31.3%, and 23.5%. Advanced tumor stage (III/IV) significantly predicted shorter survival (p < 0.001). Underweight individuals had higher mortality risk (HR = 2.79; 95% CI: 1.21–6.42; P = 0.016). In multivariate models, male gender, blood group O, and advanced disease remained independent negative prognostic indicators.
Conclusion: Male sex, advanced stage, low BMI, and blood group O were major determinants of poorer survival in pancreatic cancer. These results emphasize the need for individualized treatment and closer follow-up among high-risk groups.
Policy Brief: Original Article |
Subject:
Gastroentrology
Received: 2025/08/20 | Accepted: 2025/12/7 | Published: 2026/03/24
Received: 2025/08/20 | Accepted: 2025/12/7 | Published: 2026/03/24
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
